BELLOMO, GIOVANNI
 Distribuzione geografica
Continente #
NA - Nord America 256
EU - Europa 152
AS - Asia 131
SA - Sud America 1
Totale 540
Nazione #
US - Stati Uniti d'America 256
HK - Hong Kong 73
IE - Irlanda 55
IT - Italia 48
SG - Singapore 33
CN - Cina 19
FI - Finlandia 15
DE - Germania 14
RO - Romania 11
VN - Vietnam 5
AT - Austria 2
FR - Francia 2
RU - Federazione Russa 2
BR - Brasile 1
JP - Giappone 1
MD - Moldavia 1
NL - Olanda 1
SK - Slovacchia (Repubblica Slovacca) 1
Totale 540
Città #
Chandler 83
Hong Kong 72
Dublin 55
Singapore 21
Perugia 18
San Mateo 18
Altamura 12
Boardman 10
Helsinki 10
Timisoara 10
Lawrence 9
Medford 9
Princeton 9
Wilmington 9
Redmond 6
Andover 5
Dong Ket 5
Falls Church 5
Lappeenranta 5
Los Angeles 5
Milan 4
Des Moines 3
Rome 3
Brixen 2
Genoa 2
Munich 2
New York 2
Redwood City 2
Amsterdam 1
Ann Arbor 1
Ashburn 1
Beijing 1
Böblingen 1
Chicago 1
Chisinau 1
Curitiba 1
Ergolding 1
Fairfield 1
Gunzenhausen 1
Houston 1
Radeberg 1
Seattle 1
Secaucus 1
Shanghai 1
Tokyo 1
Trento 1
Vienna 1
Zwenkau 1
Totale 416
Nome #
CSF and Blood Biomarkers in Neuroinflammatory and Neurodegenerative Diseases: Implications for Treatment 68
A/T/(N) Profile in Cerebrospinal Fluid of Parkinson's Disease with/without Cognitive Impairment and Dementia with Lewy Bodies 52
Cerebrospinal fluid hemoglobin levels as markers of blood contamination: relevance for α-synuclein measurement 48
Measurement of CSF core Alzheimer disease biomarkers for routine clinical diagnosis: Do fresh vs frozen samples differ? 43
Validation of the LUMIPULSE automated immunoassay for the measurement of core AD biomarkers in cerebrospinal fluid 34
Specific Cerebrospinal Fluid SerpinA1 Isoform Pattern in Alzheimer's Disease 33
Neuroinflammation and Alzheimer's Disease: A Machine Learning Approach to CSF Proteomics 31
Clinical reporting following the quantification of cerebrospinal fluid biomarkers in Alzheimer's disease: An international overview 26
Cerebrospinal fluid β-synuclein as a synaptic biomarker for preclinical Alzheimer's disease 25
An unbalanced synaptic transmission: Cause or consequence of the amyloid oligomers neurotoxicity? 24
Phosphatidylethanolamine Binding Protein 1 (PEBP1) in Alzheimer's Disease: ELISA Development and Clinical Validation 22
Alpha and Beta Synucleins: From Pathophysiology to Clinical Application as Biomarkers 19
α-Synuclein Seed Amplification Assays for Diagnosing Synucleinopathies: The Way Forward 19
CSF neurochemical profile and cognitive changes in Parkinson's disease with mild cognitive impairment 15
Machine Learning Driven Profiling of Cerebrospinal Fluid Core Biomarkers in Alzheimer's Disease and Other Neurological Disorders 12
Potential diagnostic value of CSF metabolism-related proteins across the Alzheimer's disease continuum 12
LRRK2 Quantification in Cerebrospinal Fluid of Patients with Parkinson's Disease and Atypical Parkinsonian Syndromes 11
CSF Synaptic Biomarkers in AT(N)-Based Subgroups of Lewy Body Disease 11
Investigating alpha-synuclein co-pathology in Alzheimer's disease by means of cerebrospinal fluid alpha-synuclein seed amplification assay 10
Fully automated measurement of plasma Aβ42/40 and p-tau181: Analytical robustness and concordance with cerebrospinal fluid profile along the Alzheimer's disease continuum in two independent cohorts 10
CSF and plasma Aβ42/40 across Alzheimer's disease continuum: comparison of two ultrasensitive Simoa® assays targeting distinct amyloid regions 8
Methods to discover and validate biofluid-based biomarkers in neurodegenerative dementias 8
Trajectories of CSF and plasma biomarkers across Alzheimer's disease continuum: Disease staging by NF-L, p-tau181, and GFAP 8
Lipoproteins and α-synuclein in cerebrospinal fluid in Parkinson's disease: "Dangerous liaisons" on the road to neurodegeneration? 7
The Immune Signature of CSF in Multiple Sclerosis with and without Oligoclonal Bands: A Machine Learning Approach to Proximity Extension Assay Analysis 6
Required improvements for cerebrospinal fluid-based biomarker tests of Alzheimer's disease 4
Identification of natural products able to counteract the formation of advanced glycation end-products (AGEs) sustaining muscle atrophy 2
Totale 568
Categoria #
all - tutte 3.344
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 3.344


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202133 0 0 0 4 16 3 0 0 0 0 3 7
2021/202264 1 10 2 0 2 5 4 13 4 7 7 9
2022/2023259 9 60 8 17 19 22 0 20 91 1 8 4
2023/2024212 7 15 12 6 7 1 32 6 47 9 27 43
Totale 568